Lung transplantation at Duke University Medical Center.
Lung transplantation is a viable therapy for patients with a variety of end-stage lung diseases. Our active program now includes over 200 lung transplant operations with acceptable one- and 3-year survival rates of 78% and 61%. A major focus of clinical research at this institution is to design strategies to prevent the development of chronic allograft dysfunction. Our preliminary work in this regard has been encouraging. In addition, a major research focus has been to design protocols to prevent the development of posttransplant infections. Our work with aerosolized ABLC represents a major advance at our center, and additional randomized prospective studies are ongoing to define the optimal antifungal prophylaxis after transplantation. Ongoing clinical and basic research at Duke and elsewhere should continue to advance the field of clinical transplantation and ultimately lead to more acceptable long-term outcomes for lung allograft recipients.
Lau
C L
CL
Division of Cardiothoracic Surgery, Duke University Medical Center, Durham, North Carolina, USA.
Palmer
S M
SM
D'Amico
T A
TA
Tapson
V F
VF
Davis
R D
RD
D000328:Adult; D001424:Bacterial Infections / Q000517:prevention & control; D005260:Female; D006085:Graft Survival; D006785:Hospitals, University / Q000706:statistics & numerical data; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D016040:Lung Transplantation / Q000401:mortality / Q000502:physiology / Q000706:statistics & numerical data*; D008297:Male; D009181:Mycoses / Q000517:prevention & control; D009657:North Carolina; D018579:Patient Selection; D011183:Postoperative Complications / Q000517:prevention & control; D012189:Retrospective Studies; D015996:Survival Rate; D014019:Tissue Donors / Q000706:statistics & numerical data*; D014777:Virus Diseases / Q000517:prevention & control